Quantitative Ocular Surface Changes in Patients Undergoing Immune Checkpoint Inhibitor Therapy.

IF 2.6 4区医学 Q2 OPHTHALMOLOGY

Ocular Immunology and Inflammation Pub Date : 2024-10-01 Epub Date: 2023-09-18 DOI:10.1080/09273948.2023.2252892

Kevin Chen, Maria Carolina Ibañez Bruron, Sebastian Mondaca, Gonzalo Pizarro, Paulina Liberman, Meghan K Berkenstock

{"title":"Quantitative Ocular Surface Changes in Patients Undergoing Immune Checkpoint Inhibitor Therapy.","authors":"Kevin Chen, Maria Carolina Ibañez Bruron, Sebastian Mondaca, Gonzalo Pizarro, Paulina Liberman, Meghan K Berkenstock","doi":"10.1080/09273948.2023.2252892","DOIUrl":null,"url":null,"abstract":"Purpose: To describe the clinical course and evaluate treatment of ocular surface changes in patients receiving immune checkpoint inhibitor (ICI) therapy.Methods: Multiple markers of ocular surface dryness were evaluated in 16 patients on ICI therapy. The Wilcoxon rank-sum test was used to determine the significant change in the initial and final ocular surface indices.Results: Fifty percent of the eyes demonstrated worsening Schirmer I scores; 29% showed an increase in lissamine green staining. During follow-up, 43% of patients experienced a decline in OSDI scores. Treatments included preservative-free artificial tears (88%), cyclosporine (25%), topical corticosteroids (31%), warm compresses (25%); punctal plugs (13%). Median follow-up time was 3.4 months (range:0-79 ); median ICI treatment duration was 7 months (range:1-40). Four patients died during the observation period.Conclusion: A significant proportion of patients experience changes in ocular surface markers while treated with ICIs. Medical intervention can lead to stabilization of ocular surface disease.","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Immunology and Inflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09273948.2023.2252892","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To describe the clinical course and evaluate treatment of ocular surface changes in patients receiving immune checkpoint inhibitor (ICI) therapy.

Methods: Multiple markers of ocular surface dryness were evaluated in 16 patients on ICI therapy. The Wilcoxon rank-sum test was used to determine the significant change in the initial and final ocular surface indices.

Results: Fifty percent of the eyes demonstrated worsening Schirmer I scores; 29% showed an increase in lissamine green staining. During follow-up, 43% of patients experienced a decline in OSDI scores. Treatments included preservative-free artificial tears (88%), cyclosporine (25%), topical corticosteroids (31%), warm compresses (25%); punctal plugs (13%). Median follow-up time was 3.4 months (range:0-79 ); median ICI treatment duration was 7 months (range:1-40). Four patients died during the observation period.

Conclusion: A significant proportion of patients experience changes in ocular surface markers while treated with ICIs. Medical intervention can lead to stabilization of ocular surface disease.

查看原文本刊更多论文

接受免疫检查点抑制剂治疗患者的眼表定量变化

目的：描述接受免疫检查点抑制剂（ICI）治疗的患者眼表变化的临床过程并评估治疗方法：方法：对16名接受ICI治疗的患者进行眼表干燥的多种标记物评估。采用 Wilcoxon 秩和检验确定初始和最终眼表指数的显著变化：结果：50%的眼睛显示希尔默I评分恶化；29%的眼睛显示利萨明绿染色增加。在随访期间，43% 的患者的 OSDI 评分下降。治疗方法包括不含防腐剂的人工泪液（88%）、环孢素（25%）、局部皮质类固醇（31%）、热敷（25%）和穿刺栓（13%）。中位随访时间为 3.4 个月（范围：0-79）；中位 ICI 治疗时间为 7 个月（范围：1-40）。4名患者在观察期间死亡：结论：相当一部分患者在接受 ICIs 治疗期间，眼表标志物会发生变化。医学干预可使眼表疾病趋于稳定。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ocular Immunology and Inflammation 医学-眼科学

CiteScore

6.20

自引率

15.20%

发文量

285

审稿时长

6-12 weeks

期刊介绍： Ocular Immunology & Inflammation ranks 18 out of 59 in the Ophthalmology Category.Ocular Immunology and Inflammation is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and vision scientists. Published bimonthly, the journal provides an international medium for basic and clinical research reports on the ocular inflammatory response and its control by the immune system. The journal publishes original research papers, case reports, reviews, letters to the editor, meeting abstracts, and invited editorials.